Skip to main content
Erschienen in: Journal of General Internal Medicine 5/2018

05.02.2018

Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations

verfasst von: Derek N. Bremmer, PharmD, Briana E. DiSilvio, MD, Crystal Hammer, MD, Moeezullah Beg, MD, Swati Vishwanathan, MD, Daniel Speredelozzi, MD, Matthew A. Moffa, DO, Kurt Hu, MD, Rasha Abdulmassih, MD, Jina T. Makadia, MD, Rikinder Sandhu, MD, Mouhib Naddour, MD, Noreen H. Chan-Tompkins, PharmD, Tamara L. Trienski, PharmD, Courtney Watson, MPH, Terrence J. Obringer, DO, Jim Kuzyck, MT, Thomas L. Walsh, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Antibiotics are often prescribed for hospitalized patients with chronic obstructive pulmonary disease (COPD) exacerbations. The use of procalcitonin (PCT) in the management of pneumonia has safely reduced antibiotic durations, but limited data on the impact of PCT guidance on the management of COPD exacerbations remain.

Objective

To determine the impact of PCT guidance on antibiotic utilization for hospitalized adults with exacerbations of COPD.

Design

A retrospective, pre-/post-intervention cohort study was conducted to compare the management of patients admitted with COPD exacerbations before and after implementation of PCT guidance. The pre-intervention period was March 1, 2014, through October 31, 2014, and the post-intervention period was March 1, 2015, through October 31, 2015.

Participants

All patients with hospital admissions during the pre- and post-intervention period with COPD exacerbations were included. Patients with concomitant pneumonia were excluded.

Intervention

Availability of PCT laboratory values in tandem with a PCT guidance algorithm and education.

Main Measures

The primary outcome was duration of antibiotic therapy for COPD. Secondary objectives included duration of inpatient length of stay (LOS) and 30-day readmission rates.

Key Results

There were a total of 166 and 139 patients in the pre- and post-intervention cohorts, respectively. There were no differences in mean age (66.2 vs. 65.9; P = 0.82) or use of home oxygenation (34% vs. 39%; P = 0.42) in the pre- and post-intervention groups, respectively. PCT guidance was associated with a reduced number of antibiotic days (5.3 vs. 3.0; p = 0.01) and inpatient LOS (4.1 days vs. 2.9 days; P = 0.01). Respiratory-related 30-day readmission rates were unaffected (10.8% vs. 9.4%; P = 0.25).

Conclusions

Utilizing PCT guidance in the management of COPD exacerbations was associated with a decreased total duration of antibiotic therapy and hospital LOS without negatively impacting hospital readmissions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Wier LM, Elixhauser A, Pfuntner A, Au DH. Overview of hospitalizations among patients with COPD, 2008: Statistical brief #106. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006. Wier LM, Elixhauser A, Pfuntner A, Au DH. Overview of hospitalizations among patients with COPD, 2008: Statistical brief #106. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006.
3.
Zurück zum Zitat Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017: 195(5):557-582.CrossRefPubMed Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017: 195(5):557-582.CrossRefPubMed
4.
Zurück zum Zitat Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit. PLoS One. 2015:10(4):e0124374.CrossRefPubMedPubMedCentral Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit. PLoS One. 2015:10(4):e0124374.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011:17 Suppl 6:E1-59.CrossRefPubMed Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011:17 Suppl 6:E1-59.CrossRefPubMed
6.
Zurück zum Zitat Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest. 2002:122(4):1264-1270.CrossRefPubMed Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest. 2002:122(4):1264-1270.CrossRefPubMed
7.
Zurück zum Zitat Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009:48(1):1-12.CrossRefPubMed Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009:48(1):1-12.CrossRefPubMed
8.
Zurück zum Zitat Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000:181(1):176-180.CrossRefPubMed Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000:181(1):176-180.CrossRefPubMed
9.
Zurück zum Zitat Haeuptle J, Zaborsky R, Fiumefreddo R, et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis. 2009:28(1):55-60.CrossRefPubMed Haeuptle J, Zaborsky R, Fiumefreddo R, et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis. 2009:28(1):55-60.CrossRefPubMed
10.
Zurück zum Zitat Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001:86(1):396-404.PubMed Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001:86(1):396-404.PubMed
11.
Zurück zum Zitat Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007:30(3):556-573.CrossRefPubMed Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007:30(3):556-573.CrossRefPubMed
12.
Zurück zum Zitat Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology. 2005:146(6):2699-2708.CrossRefPubMed Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology. 2005:146(6):2699-2708.CrossRefPubMed
13.
Zurück zum Zitat Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012(9):Cd007498. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012(9):Cd007498.
14.
Zurück zum Zitat Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009:302(10):1059-1066.CrossRefPubMed Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009:302(10):1059-1066.CrossRefPubMed
16.
Zurück zum Zitat Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016:164(6):425-434.CrossRefPubMed Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016:164(6):425-434.CrossRefPubMed
17.
Zurück zum Zitat Mathiodakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, et al. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev. 2017:26:160073.CrossRef Mathiodakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, et al. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev. 2017:26:160073.CrossRef
18.
Zurück zum Zitat Verduri A, Luppi F, D’Amico R, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One. 2015;10:e0118241.CrossRefPubMedPubMedCentral Verduri A, Luppi F, D’Amico R, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One. 2015;10:e0118241.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9-19.CrossRefPubMed Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9-19.CrossRefPubMed
20.
Zurück zum Zitat Van der Maas ME, Mantjes G, Steuten LM. Procalcitonin biomarker algorithm reduces antibiotic prescriptions, duration of therapy, and costs in chronic obstructive pulmonary disease: a Comparison in The Netherlands, Germany, and the United Kingdom. OMICS. 2017:21(4):232-243.CrossRefPubMed Van der Maas ME, Mantjes G, Steuten LM. Procalcitonin biomarker algorithm reduces antibiotic prescriptions, duration of therapy, and costs in chronic obstructive pulmonary disease: a Comparison in The Netherlands, Germany, and the United Kingdom. OMICS. 2017:21(4):232-243.CrossRefPubMed
Metadaten
Titel
Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations
verfasst von
Derek N. Bremmer, PharmD
Briana E. DiSilvio, MD
Crystal Hammer, MD
Moeezullah Beg, MD
Swati Vishwanathan, MD
Daniel Speredelozzi, MD
Matthew A. Moffa, DO
Kurt Hu, MD
Rasha Abdulmassih, MD
Jina T. Makadia, MD
Rikinder Sandhu, MD
Mouhib Naddour, MD
Noreen H. Chan-Tompkins, PharmD
Tamara L. Trienski, PharmD
Courtney Watson, MPH
Terrence J. Obringer, DO
Jim Kuzyck, MT
Thomas L. Walsh, MD
Publikationsdatum
05.02.2018
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 5/2018
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-018-4312-2

Weitere Artikel der Ausgabe 5/2018

Journal of General Internal Medicine 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.